Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AT8847
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $14.85 | Total: $1,485.00 |
1 | 50 | $17.16 | Total: $858.00 |
1 | 25 | $20.13 | Total: $503.25 |
1 | 10 | $23.76 | Total: $237.60 |
1 | 5 | $28.05 | Total: $140.25 |
Molecular Formula | C31H40F2N7O8PS |
Molecular Weight | 739.7 |
CAS Numbers | 914361-45-8 |
Storage Condition | 0C Short Term, -20C Long Term |
Solubility | DMSO |
Purity | 98% by HPLC |
SMILES Code | N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN |
References | Diniz LF, Mazzeti AL, Caldas IS, Ribeiro I, Bahia MT. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018;62[6] e00401-18. Published 2018 May 25. doi 10.1128AAC.00401-18Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis A multicenter, double-blind, randomized phase III study. J Dermatol. 2018;45[10] 1151-1159. doi 10.11111346-8138.14607 |